Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Meissner

Showing results (401-410 of 436) with videos related to

Pageof 44
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 27, 2007
Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitorsMahbub Alam, Rebekah E Beevers, Tom Ceska, et al.
Annals of Neurology|August 26, 2025
Disease Progression in Multiple System Atrophy: The ASPIRE Multi-Modal Biomarker StudyMargherita Fabbri, Natalia Del Campo, Wassilios G Meissner, et al.
Neurology|May 14, 2020
Liver transplantation as a rescue therapy for severe neurologic forms of Wilson diseaseAurélia Poujois, Rodolphe Sobesky, Wassilios G Meissner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 1, 2024
Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European CountriesChristopher Kruse, Anna Lipinski, Malte Verheyen, et al.
The Journal of Clinical Psychiatry|January 30, 2019
Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ CohortDavid Misdrahi, Arnaud Tessier, Antoine Daubigney, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 21, 2022
The Movement Disorder Society Criteria for the Diagnosis of Multiple System AtrophyGregor K Wenning, Iva Stankovic, Luca Vignatelli, et al.
Nature|November 5, 2025
Synthetic α-synuclein fibrils replicate in mice causing MSA-like pathologyDomenic Burger, Marianna Kashyrina, Lukas van den Heuvel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 29, 2021
A Modified Progressive Supranuclear Palsy Rating ScaleMarie-Therese Grötsch, Gesine Respondek, Carlo Colosimo, et al.
Journal of Parkinson'S Disease|February 20, 2025
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studiesDavid Devos, Olivier Rascol, Wassilios G Meissner, et al.
Pageof 44

Showing results (401-410 of 436) with videos related to

Sort By:
Pageof 44
Bioorganic & Medicinal Chemistry Letters|April 27, 2007
Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitorsMahbub Alam, Rebekah E Beevers, Tom Ceska, et al.
Annals of Neurology|August 26, 2025
Disease Progression in Multiple System Atrophy: The ASPIRE Multi-Modal Biomarker StudyMargherita Fabbri, Natalia Del Campo, Wassilios G Meissner, et al.
Neurology|May 14, 2020
Liver transplantation as a rescue therapy for severe neurologic forms of Wilson diseaseAurélia Poujois, Rodolphe Sobesky, Wassilios G Meissner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 1, 2024
Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European CountriesChristopher Kruse, Anna Lipinski, Malte Verheyen, et al.
The Journal of Clinical Psychiatry|January 30, 2019
Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ CohortDavid Misdrahi, Arnaud Tessier, Antoine Daubigney, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 21, 2022
The Movement Disorder Society Criteria for the Diagnosis of Multiple System AtrophyGregor K Wenning, Iva Stankovic, Luca Vignatelli, et al.
Nature|November 5, 2025
Synthetic α-synuclein fibrils replicate in mice causing MSA-like pathologyDomenic Burger, Marianna Kashyrina, Lukas van den Heuvel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 29, 2021
A Modified Progressive Supranuclear Palsy Rating ScaleMarie-Therese Grötsch, Gesine Respondek, Carlo Colosimo, et al.
Journal of Parkinson'S Disease|February 20, 2025
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studiesDavid Devos, Olivier Rascol, Wassilios G Meissner, et al.
Pageof 44